7 Undervalued Biotechnology & Medical Research Stocks for Thursday, February 22
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Thursday, February 22 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Commentary & Analysis
4 Undervalued Biotechnology & Medical Research Stocks for Wednesday, January 03
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Wednesday, January 03 based on AAII’s Stock Grades.Jack Gilleland
Why Clearmind Medicine Inc’s (CMND) Stock Is Up 14.52%
As of Wednesday, January 25, Clearmind Medicine Inc’s CMND share price has surged by 14.52%, which has investors questioning if this is right time to sell.Jack Gilleland
Is Clearmind Medicine Inc (CMND) Stock a Good Investment?
Learn more about Clearmind Medicine Inc's (CMND) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | CMND | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.8 | $519.2 | 2% |
|
| Shares Out (Mil) | 0.2 | 42.8 | 1% |
|
| Institutional Ownership | 78.1% | 82.8% | 47% |
|
| Float (Mil) | 0.4 | 44.4 | 1% |
|
| Beta | 0.46 | 0.71 | 26% |
|
| Avg Daily Volume (000s) | 39 | 394 | 26% |
|
| Price Change (52-week) |
(97.9%) | 60.2% | 2% |
|
| Growth | CMND | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (67.0%) | (2.0%) | 4% |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CMND | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 31% |
|
| EPS (TTM) | ($118.410) | ($0.700) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($7) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | ($11) | $494 | 2% |
|
| Valuation | CMND | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.14 | 2.31 | 2% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CMND | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (71.8%) | (22.2%) | 8% |
|
| ROE | (107.0%) | (21.4%) | 8% |
|
| Liabilities to Assets | 23.4% | 32.8% | 16% |
|
| F-Score | 2 | 3 | na |
|
Clearmind Medicine Inc. did not pass any screens on 10/9/2026.
